Tumor Steatosis and Glutamine Synthetase Expression in Patients with Advanced HCC Receiving Atezolizumab plus Bevacizumab Therapy.

Yutaka Kurebayashi,Hanako Tsujikawa,Katsutoshi Sugimoto,Daisuke Yunaiyama,Yoichi Araki,Kazuhiro Saito,Hiroshi Takahashi,Tatsuya Kakegawa,Takuya Wada,Yusuke Tomita,Masakazu Abe,Yu Yoshimasu,Hirohito Takeuchi, Taiki Hirata,Kentaro Sakamaki, Kazuhiro Kakimi,Toshitaka Nagao,Takao Itoi,Michiie Sakamoto

Hepatology research : the official journal of the Japan Society of Hepatology（2023）

引用 0|浏览6

暂无评分

摘要

The biology and TIME of HCC were strikingly different in advanced HCC compared with those of surgically resected HCC. Two metabolism-related factors, pathologically-determined tumor steatosis and/or GS expression, and MRI-determined tumor steatosis, were found to be the most significant prognostic indicators for Atezo+Bev therapy in advanced HCC. This article is protected by copyright. All rights reserved.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要